Wednesday, July 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

The CDC is still trying to fix its data problem

Two years into the COVID-19 pandemic, the Centers for Disease Control and Prevention is still trying to improve the way it collects and analyzes public health data.

A March 16th email reviewed by Politico from Dan Jernigan, the CDC’s deputy director for Public Health Science and Surveillance, mentioned the Data Modernization Initiative — a plan that would include integrating state and federal data systems and giving states funding to hire staffers to work with data.

The COVID-19 pandemic highlighted the stark limitations of the US public health data systems: information is siloed at individual hospitals and local health departments and often takes a winding path before it gets to the federal level. Labs couldn’t send information on cases straight from their own data systems to the CDC, relying on emails and faxes to pass along information. Some data-collection programs required manual entry. It took weeks and months for federal agencies to figure out answers to questions that other countries had the systems to answer in real-time.

Source: The Verge

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!